Journal of Atherosclerosis and Thrombosis · 2011 · 45 citations · 26 references
MedicineCardiologyClinical CardiologyInflammationInterventional CardiologyCardiovascular DiseaseCoronary Artery DiseaseIschemic Heart DiseasePercutaneous Coronary InterventionCoronary Stent RestenosisElective Percutaneous Coronary InterventionKaplan-meier Survival EstimatesVascular Resistance
AIM: Resistin is an adipocytokine that may link inflammation and atherosclerosis.We studied the associations of resistin levels with cardiovascular events and restenosis. METHODS: We measured pre-procedural serum resistin levels in 140 patients with coronary artery disease undergoing elective percutaneous coronary intervention (PCI), of whom 97 had a stent. Restenosis was defined as > 50% stenosis at follow-up angiography. Patients were followed for 3 years for major adverse cardiovascular events (MACE). RESULTS: At 8±6 months after PCI, reangiography was performed in 94 (67%) patients, of whom 42 had restenosis. Between 42 patients with restenosis and 52 without restenosis, resistin (4.5±2.6 vs. 4.5±2.5 ng/mL) and Creactive protein (CRP) (median 0.70 vs. 0.70 mg/L) levels did not differ. During 3-year follow-up, MACE occurred in 24 patients (1 death, 21 unstable angina, 2 stroke). Compared with 116 patients without MACE, 24 with MACE had higher resistin (5.4±2.4 vs. 4.3±2.5 ng/mL) and CRP (1.30 vs. 0.60 mg/L) levels (p< 0.05). Patients with MACE more often had resistin >4.0 ng/mL than without MACE (75% vs. 35%, p< 0.001). Resistin correlated with CRP levels (r= 0.31). To clarify the association between MACE and resistin, patients were divided into 2 groups by resistin levels. Kaplan-Meier analysis showed a lower event-free survival rate in patients with resistin > 4.0 ng/mL than without it (p< 0.001). On multivariate analysis, resistin, but not CRP, was an independent predictor of MACE. The hazard ratio for MACE was 3.6 (95%CI=1.4-9.2) for resistin > 4.0 ng/mL. CONCLUSION: Serum resistin levels were found to be associated with further cardiovascular events in patients undergoing PCI.
26
The hormone resistin links obesity to diabetes
Claire M. Steppan, Shannon T. Bailey, Savitha Bhat et al. · Nature · 2001 · 4.8K citations
Resistin Is an Inflammatory Marker of Atherosclerosis in Humans
Muredach P. Reilly, Michael Lehrke, Megan L. Wolfe et al. · Circulation · 2005 · 904 citations · Full text
Resistin Promotes Endothelial Cell Activation
Subodh Verma, Shuhong Li, Chao‐Hung Wang et al. · Circulation · 2003 · 665 citations · Full text